COMP <GO>
OPCH vs HIMS // EV/EBITDA & P/E VALUATION
Option Care Health Inc. (NASDAQ) VS. Hims & Hers Health Inc. (NYSE) • 15-METRIC TALLY: OPCH 7
— HIMS 6
▲ EV/EBITDA & P/E VALUATION LEADER: OPCH
LAST: $31.85 (+1.79%) • MKT CAP: $4.77B
valuation
15.3x
LAST: $29.67 (+1.19%) • MKT CAP: $6.92B
valuation
37.7x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OPCH VS. HIMS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | OPCH | HIMS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 19.30% | 73.80% | -54.50 | HIMS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.90% | 8.40% | +3.50 | OPCH | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 15.3x | 37.7x | -22.40 | OPCH | /valuation <GO> |
| Free Cash Flow Yield | 4.55% | 2.81% | +1.74 | OPCH | /fcf-yield <GO> |
| Operating Margin | 6.00% | 4.50% | +1.50 | OPCH | /operating-margins <GO> |
| Net Profit Margin | 3.70% | 5.50% | -1.80 | HIMS | /net-margins <GO> |
| Revenue Growth (YoY) | 13.00% | 59.00% | -46.00 | HIMS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.81 | 3.95 | -0.14 | HIMS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | HIMS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 84.3 | 53.1 | +31.20 | OPCH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 1.05 | +0.05 | OPCH | /macro-sensitivity <GO> |
| Forward P/E Multiple | 19.3x | 45.3x | -26.00 | OPCH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.77B | $6.92B | -$2.15B | HIMS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | OPCH REV | HIMS REV | OPCH GROSS % | HIMS GROSS % | OPCH FCF | HIMS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.65B | $2.35B | 19.3% | 73.8% | $217.1M | $194.4M |
| FY 2024 | $5.00B | $1.48B | 20.3% | 79.5% | $287.8M | $184.6M |
| FY 2023 | $4.30B | $872.0M | — | — | $177.7M | $34.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OPCH // BETA 1.10
HIMS // BETA 1.05